{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:46:11Z","timestamp":1780692371448,"version":"3.54.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory hematological malignancies but is frequently complicated by immune effector cell-associated neurotoxicity syndrome (ICANS). Early clinical recognition remains challenging, as the commonly used Immune Effector Cell-Associated Encephalopathy (ICE) score lacks sensitivity for subtle deficits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective bicentric study, 100 patients treated with CAR T-cells at Hannover Medical School and Charit\u00e9 - Universit\u00e4tsmedizin Berlin underwent systematic neurological assessments using both ICE and the newly developed Berlin-Hannover ICANS Severity Assessment (BHISA). Examinations were performed at baseline prior to CAR T-cell infusion, on day 6\u20137 (\u00b11\u202fday) post-infusion, and during ICANS episodes. Data on the clinical course, other toxicities, comorbidities, CAR T-cell products, and ICANS treatment were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-seven patients (37%) developed ICANS, which was associated with preceding cytokine release syndrome and specific CAR T-cell products. While ICE scores clustered at maximum values both at baseline and follow-up, BHISA showed a broader distribution and higher sensitivity to subtle changes. Correlation analyses confirmed agreement between ICE and BHISA, but BHISA captured early cognitive decline more reliably. Receiver operating characteristic analyses demonstrated comparable diagnostic accuracy (BHISA: AUC\u202f=\u202f0.783, ICE: AUC\u202f=\u202f0,777), with consistently higher sensitivity of BHISA at matched specificity. (Specificity target\u202f=\u202f0.7, BHISA sensitivity\u202f=\u202f0.743, ICE sensitivity\u202f=\u202f0.571; Specificity target\u202f=\u202f0.8, BHISA sensitivity\u202f=\u202f0.629, ICE sensitivity\u202f=\u202f0.571).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BHISA may provide a more sensitive and more differentiated screening tool for ICANS than ICE by incorporating additional cognitive and motor domains, while remaining easy to use. This may enable earlier and more nuanced detection of CAR T related neurotoxicity, potentially improving patient monitoring across a heterogeneous population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1726779","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:37:16Z","timestamp":1768973836000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The Berlin-Hannover ICANS severity assessment\u2013a novel bedside test to evaluate CAR T-cell-associated neurotoxicity"],"prefix":"10.3389","volume":"17","author":[{"given":"Lotta","family":"V\u00f6lker","sequence":"first","affiliation":[{"name":"Department of Neurology, Hannover Medical School","place":["Hannover, Germany"]},{"name":"KlinStrucMed Program, Dean\u2019s Office for Academic Career Development, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"M\u00fcller-Jensen","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin, Klinik f\u00fcr Neurologie mit Experimenteller Neurologie","place":["Berlin, Germany"]},{"name":"Berlin Institute of Health at Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Carl","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Nay","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiemo Malte","family":"M\u00f6llenkamp","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School","place":["Hannover, Germany"]},{"name":"Department of Neurology, University Hospital Munster","place":["Munster, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schultze-Florey","sequence":"additional","affiliation":[{"name":"Department of Haematology, Haemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Grote-Levi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin F.","family":"Jendretzky","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz Felix","family":"Konen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"K\u00f6necke","sequence":"additional","affiliation":[{"name":"Department of Haematology, Haemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[{"name":"Department of Haematology, Haemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Panagiota","sequence":"additional","affiliation":[{"name":"Department of Haematology, Haemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[{"name":"Department of Haematology, Haemostaseology, Oncology and Stem Cell Transplantation, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bullinger","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oncology and Tumour Immunology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Damm","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oncology and Tumour Immunology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Frick","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oncology and Tumour Immunology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Penack","sequence":"additional","affiliation":[{"name":"Department of Haematology, Oncology and Tumour Immunology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Berlin Institute of Health at Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Anil","family":"Bu\u00df","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin, Klinik f\u00fcr Neurologie mit Experimenteller Neurologie","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Boehmerle","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin, Klinik f\u00fcr Neurologie mit Experimenteller Neurologie","place":["Berlin, Germany"]},{"name":"Berlin Institute of Health at Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Endres","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin, Klinik f\u00fcr Neurologie mit Experimenteller Neurologie","place":["Berlin, Germany"]},{"name":"Berlin Institute of Health at Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]},{"name":"Center for Stroke Research Berlin, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]},{"name":"German Center for Neurodegenerative Diseases (DZNE)","place":["Berlin, Germany"]},{"name":"German Centre for Cardiovascular Diseases (DZHK)","place":["Berlin, Germany"]},{"name":"German Center for Mental Health (DZPG)","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Gudi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Huehnchen","sequence":"additional","affiliation":[{"name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin, Klinik f\u00fcr Neurologie mit Experimenteller Neurologie","place":["Berlin, Germany"]},{"name":"Berlin Institute of Health at Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"M\u00f6hn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School","place":["Hannover, Germany"]},{"name":"Department of Neurology, University Hospital Bonn","place":["Bonn, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR t cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","article-title":"Chimeric antigen receptor T-cell therapies for lymphoma","volume":"15","author":"Brudno","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"103126","DOI":"10.1016\/j.jaut.2023.103126","article-title":"Cognition following chimeric antigen receptor T-cell therapy: a systematic review","volume":"140","author":"Kazzi","year":"2023","journal-title":"J Autoimmun"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41419-018-0918-x","article-title":"The biological basis and clinical symptoms of CAR-T therapy-associated toxicites","volume":"9","author":"Titov","year":"2018","journal-title":"Cell Death Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biologic correlates of neurotoxicity associated with CAR T cell therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL)","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1158\/1078-0432.CCR-22-0822","article-title":"Comprehensive serum proteome profiling of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome patients with B-cell ALL receiving CAR T19","volume":"28","author":"Diorio","year":"2022","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fneur.2023.1110647","article-title":"A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome","volume":"14","author":"Butt","year":"2023","journal-title":"Front Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/jnnp-2024-333924","article-title":"Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy","volume":"96","author":"Vonberg","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/ene.16174","article-title":"Patterns of neurotoxicity among patients receiving chimeric antigen receptor T-cell therapy: a single-Centre cohort study. Euro J of","volume":"31","author":"Sales","year":"2024","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.clml.2024.12.011","article-title":"Novel neurocognitive testing tool for early neurotoxicity detection following anti-CD19 and anti-BCMA chimeric antigen receptor (CAR) T-cell therapy: a pilot study","volume":"25","author":"Suresh","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1016\/j.bbmt.2020.07.031","article-title":"Identification of neurotoxicity after chimeric antigen receptor (CAR) T cell infusion without deterioration in the immune effector cell encephalopathy (ICE) score","volume":"26","author":"Herr","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3892\/etm.2015.2689","article-title":"Heterogeneity of clinical features and corresponding antibodies in seven patients with anti-NMDA receptor encephalitis","volume":"10","author":"Suhs","year":"2015","journal-title":"Exp Ther Med"},{"key":"ref20","first-page":"3","article-title":"The ten-twenty electrode system of the international federation. The International Federation of Clinical Neurophysiology","volume":"52","author":"Klem","year":"1999","journal-title":"Electroencephalogr Clin Neurophysiol Suppl"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1007\/s10072-023-06841-6","article-title":"Pre-existing frontal lobe dysfunction signs as predictors of subsequent neurotoxicity in CAR T cell therapy: insights from a case series","volume":"44","author":"Fontanelli","year":"2023","journal-title":"Neurol Sci"},{"key":"ref22","year":"2025"},{"key":"ref23","author":"Wickham","year":"2025"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"JOSS"},{"key":"ref25","author":"Firke","year":"2024"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v105.i07","article-title":"Expanding tidy data principles to facilitate missing data exploration, visualization and assessment of imputations","volume":"105","author":"Tierney","year":"2023","journal-title":"J Stat Softw"},{"key":"ref27","author":"Gohel","year":"2025"},{"key":"ref28","author":"Kassambara","year":"2025"},{"key":"ref29","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant graphics for data analysis","author":"Wickham","year":"2016"},{"key":"ref30","author":"Wilke","year":"2025"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1392831","DOI":"10.3389\/fneur.2024.1392831","article-title":"Incidence of immune effector cell-associated neurotoxicity among patients treated with CAR T-cell therapy for hematologic malignancies: systematic review and meta-analysis","volume":"15","author":"Han","year":"2024","journal-title":"Front Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1182\/bloodadvances.2024015779","article-title":"Outcomes of brexucabtagene autoleucel in patients with relapsed\/refractory acute lymphoblastic leukemia with CNS involvement","volume":"9","author":"Muhsen","year":"2025","journal-title":"Blood Adv"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"S272","DOI":"10.1182\/blood-2021-146060","article-title":"Updated results from the CARTITUDE-1 study of ciltacabtagene autoleucel, a B-cell maturation antigen\u2013directed chimeric antigen receptor T cell therapy, in relapsed\/refractory multiple myeloma","volume":"43","author":"Usmani","year":"2021","journal-title":"Hematol Transfus Cell Ther"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"e70831","DOI":"10.1002\/cam4.70831","article-title":"Sex differences in outcomes of chimeric antigen receptor (CAR) T-cell therapy","volume":"14","author":"Tan","year":"2025","journal-title":"Cancer Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1210\/endocr\/bqaa127","article-title":"Estradiol, progesterone, immunomodulation, and COVID-19 outcomes","volume":"161","author":"Mauvais-Jarvis","year":"2020","journal-title":"Endocrinology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1080\/10428194.2022.2074990","article-title":"Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy","volume":"63","author":"Lapidus","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1182\/bloodadvances.2021006144","article-title":"Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment","volume":"6","author":"Schoeberl","year":"2022","journal-title":"Blood Adv"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1726779\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:37:19Z","timestamp":1768973839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1726779\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":43,"alternative-id":["10.3389\/fneur.2026.1726779"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1726779","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"article-number":"1726779"}}